ly2787106
mAbexperimental
Hepcidin is a protein that in humans is encoded by the HAMP gene. Hepcidin is a key regulator of the entry of iron into the circulation in mammals. — Wikipedia
Clinical trial activity
4 trials · 6 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Jan 1, 2010 (NCT01340976)
Timeline
Indications
Mechanism of action
- HepcidinINHIBITOR
HAMP inhibitor
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaHepcidin ↗
- ChEMBLCHEMBL2109440 ↗
Also known as
- hepcidin
- hepcidin
- ly2787106
- ly-2787106
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03381833 | Phase 2 | Nov 30, 2017 | La Jolla Pharmaceutical Company |
| NCT03395704 | Phase 2 | Nov 29, 2017 | La Jolla Pharmaceutical Company, Pharmaceutical Research Associates, Inc. (PRA) |
| NCT02276690 | N/A | Aug 1, 2014 | St Eloi University Hospital, University of Angers, University of Montpellier |
| NCT01340976 | Phase 1 | Jan 1, 2010 | Eli Lilly |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (6)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| La Jolla Pharmaceutical Company | For profit | 2 | 2 | 1 | 2017 |
| Eli Lilly | For profit | 1 | 1 | 1 | 2010 |
| Pharmaceutical Research Associates, Inc. (PRA) | For profit | 1 | 0 | 1 | 2017 |
| St Eloi University Hospital | Academic/Hospital | 1 | 0 | 1 | 2014 |
| University of Angers | Academic/Hospital | 1 | 0 | 1 | 2014 |
| University of Montpellier | Academic/Hospital | 1 | 1 | 1 | 2014 |
6 organizations
Page 1 / 1